Compounds 3,30 5–731 and 832 were prepared according to
reported procedures.
chromatography (Al2O3, CH2Cl2 to CH2Cl2–acetone 97 : 3). The
compound was obtained as a purple solid (100 mg, 68%).
1H-NMR (300 MHz, CDCl3) δ: −2.82 (s, br, 2H, NH), 1.92
(s, 12H, CH3ortho), 2.71 (s, 6H, CH3para), 7.38 (s, 4H, Hmeta),
8.25 (dd, J = 4.4 and 1.7 Hz, 4H, Hpyridyl), 8.86 (m, 4H, Hβpyr),
8.92 (d, J = 4.6 Hz, 2H, Hβpyr), 9.09 (dd, J = 4.4 and 1.7 Hz,
4H, Hpyridyl), 9.33 (d, J = 4.6 Hz, 2H, Hβpyr), 10.20 (s, 1H,
Compound 1. In a Schlenck tube, a solution of 5,15-dimesi-
tyl-10,20-dibromoporphyrin 6 (100 mg, 0.14 mmol, 1 equiv.),
4-ethynyl pyridine 8 (42 mg, 0.42 mmol, 3 equiv.), Pd2dba3
(64 mg, 0.07 mmol, 0.5 equiv.) and AsPh3 (85.7 mg, 0.28 mmol,
2 equiv.) in degassed triethylamine (3 mL) and dry THF (7 mL)
was heated at 75 °C for 1 h. The mixture was cooled to room
temperature and the solvent was evaporated under reduced
pressure. The product was washed with methanol (3 × 10 mL)
and purified by column chromatography (Al2O3, CH2Cl2) to
afford the pure compound as a green solid (84 mg, 80%).
H
meso); 13C-NMR (90 MHz, CDCl3) δ: 21.5 (CH3), 21.7 (CH3),
104.9 (CH), 116.0 (C), 118.2 (C), 127.9 (C), 129.4 (CH), 130.3
(CH), 130.5 (CH), 130.9 (CH), 131.8 (CH), 137.8 (C), 138.0
(C), 139.4 (C), 148.2 (CH), 150.7 (C). UV-Vis. (CH2Cl2) λmax
/
nm (ε × 104/L mol−1 cm−1): 419 (39.13), 508 (1.61), 539 (0.28),
582 (0.46), 637 (0.11). IR(ATR)/cm−1 νmax: 1597, 1558, 1464,
1440, 1334, 1270, 1244, 1218, 1193, 1174, 1072 1051, 997,
961, 844, 797, 784, 736, 705, 696. m/z (HRM+) calc.: 624.312
[M + H+], found: 624.311.
1H-NMR (300 MHz, CDCl3) δ: −1.89 (s, br, 2H, NH), 1.87
(s, 12H, CH3ortho), 2.66 (s, 6H, CH3para), 7.32 (s, 4H, Hmeta),
7.84 (d, J = 6.0 Hz, 4H, Hpyridyl), 8.72 (d, J = 4.8 Hz, 4H,
H
βpyr), 8.82 (d, J = 6.0 Hz, 4H, Hpyridyl), 9.59 (d, J = 4.8 Hz,
4H, Hβpyr); 13C-NMR (90 MHz, CDCl3) δ: 21.6 (CH3), 30.9
Compound 11. 5,15-Dimesityl-10-(pyridin-4-yl)porphyrin 10
(85 mg, 0.136 mmol, 1 equiv.) in CHCl3 (65 mL) and pyridine
(65 μL) was treated with NBS (27 mg, 1.1 equiv.) at 0 °C for
30 min. The mixture was quenched with acetone (15 mL). The
solvent was evaporated under reduced pressure and the product
was purified by column chromatography (Al2O3, CH2Cl2–
acetone 95 : 5). The pure product was obtained as a purple solid
(80 mg, 84%).
(CH3), 94.2 (C), 125.4 (CH), 128.0 (CH), 138.2 (CH), 139.1
(CH), 148.4 (C), 148.3 (C), 150.1 (CH). UV-Vis. (CH2Cl2) λmax
/
nm (ε × 104/L mol−1 cm−1): 441 (34.17), 526 (0.91), 596 (3.39),
624 (1.85), 687 (2.09). IR (ATR)/cm−1 νmax: 2205, 1734, 1591,
1558, 1538, 1524, 1491, 1471, 1452, 1399, 1368, 1344, 1315,
1261, 1213, 1194, 1159, 1001, 976, 947, 925, 858, 811, 796, 726,
704. m/z (HRM+): calc.: 749.339 [M + H+], found: 749.338.
1H-NMR (300 MHz, CDCl3) δ: −2.58 (s, br, 2H, NH), 1.85
(s, 12H, CH3ortho), 2.66 (s, 6H, CH3para), 7.32 (s, 4H, Hmeta),
8.18 (dd, J = 4.4 and 1.5 Hz, 2H, Hpyridyl), 8.72 (s, 4H, Hβpyr),
8.78 (d, J = 4.8 Hz, 2H, Hβpyr), 9.04 (dd, J = 4.4 and 1.5 Hz,
2H, Hpyridyl), 9.64 (d, J = 4.8 Hz, 2H, Hβpyr); 13C-NMR
(90 MHz, CDCl3) δ: 21.5 (CH3), 21.6 (CH3), 103.0 (CBr), 116.4
(C), 119.5 (C), 127.9 (CH), 129.3 (CH), 137.8 (C), 138.1 (CH),
139.3 (C), 148.3 (CH), 150.0 (C). UV-Vis. (CH2Cl2) λmax/nm
(ε × 104/L mol−1 cm−1): 419 (42.60), 517 (1.70), 551 (0.72),
595 (0.49), 651 (0.41). IR(ATR)/cm−1 νmax: 3342, 3075, 2919,
2360, 2343, 1594, 1578, 1472, 1400, 1348, 1213, 1188, 1068,
971, 881, 846, 815, 801, 788, 737, 723, 657, 642. m/z (HRM+)
calc.: 702.223 [M + H+], found: 702.223.
Compound 2. In a Schlenck tube, a solution of 5,15-dimesi-
tyl-10-(pyridin-4-yl)-20-bromoporphyrin
11
(100
mg,
0.143 mmol, 1 equiv.), 4-ethynyl pyridine 8 (21.8 mg,
0.22 mmol, 1.5 equiv.), Pd2dba3 (32.7 mg, 0.036 mmol, 0.25
equiv.) and AsPh3 (43.8 mg, 0.143 mmol, 1 equiv.) in degassed
Et3N (3 mL) and dry THF (7 mL) was heated at 75 °C for 2 h.
The mixture was cooled to room temperature and the solvent
was evaporated under reduced pressure. The product was washed
with MeOH (3 × 10 mL) and purified by column chromato-
graphy (Al2O3, CH2Cl2) to afford the pure compound as a
purple solid (70 mg, 68%).
1H-NMR (300 MHz, CDCl3) δ: −2.20 (s, br, 2H, NH), 1.88 (s,
12H, CH3ortho), 2.67 (s, 6H, CH3para), 7.33 (s, 4H, Hmeta), 7.85
(br, 2H, Hpyridyl), 8.17 (br, 2H, Hpyridyl), 8.71 (s, 4H, Hβpyr),
8.78–8.88 (m, 4H, Hpyridyl and Hβpyr), 9.04 (s, br, Hpyridyl), 9.68
(d, J = 4.2 Hz, 2H, Hβpyr); 13C-NMR (90 MHz, CDCl3) δ: 21.9
(CH3), 22.1 (CH3), 77.7 (C), 94.2 (C), 96.8 (C), 97.9 (C), 118.5
(C), 120.6 (CH), 125.8 (C), 128.4 (CH), 129.6 (CH), 132.4, 138.0
(CH), 138.6 (C), 139.7 (CH), 148.8 (CH), 150.4 (CH), 150.5 (C).
UV-Vis. (CH2Cl2) λmax/nm (ε × 104/L mol−1 cm−1): 433
(44.71), 531 (1.26), 572 (2.66), 602 (0.74), 665 (1.17). IR
(ATR)/cm−1 νmax: 3326, 2964, 2919, 2539, 2323, 2200, 1591,
1561, 1536, 1472, 1536, 1472, 1454, 1404, 1377, 1345, 1218,
1193, 1151, 1070, 999, 977, 970, 929, 883, 850, 800, 789, 736,
728. m/z (HRM+) calc.: 725.339 [M + H+], found: 725.335.
Crystallisation conditions
1-Zn: in a crystallization tube (4 mm diameter, 15 cm height),
upon slow diffusion at room temperature of a MeOH solution
(2 mL) of Zn(OAc)2 (2 mg, 4 mmol L−1) into a CH2Cl2 solution
(0.5 mL) of compound 1 (0.38 mg, 1 mmol L−1) purple crystals
of 1-Zn were obtained after 14 days.
2-Zn: in a crystallization tube (4 mm diameter, 15 cm height),
upon slow diffusion at room temperature of a MeOH solution
(2 mL) of Zn(OAc)2 (2 mg, 4 mmol L−1) into a CHCl3 solution
(0.5 mL) of compound 2 (0.36 mg, 1 mmol L−1) two types
of purple crystals (rod and rhombic morphologies representing
ca. 90% and 10% respectively) were obtained after 10 days.
Compound
10. 5,15-Dimesityl-10-bromoporphyrin
7
(147 mg, 0.235 mmol, 1 equiv.), 4-pyridine boronic acid 9
(60 mg, 0.5 mmol, 2.1 equiv.) and Na2CO3 (60 mg, 0.7 mmol, 3
equiv.) in a mixture of toluene (8 mL), MeOH (5 mL) and water
(0.5 mL) were degassed with argon for 15 min. Then Pd(PPh3)4
(13.5 mg, 0.01 mmol, 0.05 equiv.) was added and the mixture
was refluxed at 95 °C for 3 days. The solvent was evaporated
under reduced pressure and the dark solid was purified by column
Results and discussion
Design of ligands 1 and 2
The majority of the reported coordination networks is often
based on two or three component systems. Furthermore, since
14684 | Dalton Trans., 2012, 41, 14683–14689
This journal is © The Royal Society of Chemistry 2012